Issue Date: March 20, 2017
Intrexon reorganizes its pharma businesses
As part of a review of its health-related businesses, the synthetic biology company Intrexon has consolidated all its health care assets and put them in a new subsidiary called Precigen. Through collaborations, joint ventures, and the start-up Xogenex, Intrexon’s synthetic biology technology is used in multiple gene- and cell-therapy candidates. Three clinical trials are under way, and up to 10 more could begin this year, the firm says. Separately, Intrexon President Geno Germano, who was . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society